A randomised, double blind, placebo-controlled study of the effects of Dehydroepiandrosterone (DHEA) replacement on vascular function in patients with primary and secondary adrenal insufficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46268487

Enrollment

Registered

2005-06-10

Start date

2005-05-01

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary and secondary adrenal insufficiency Nutritional, Metabolic, Endocrine

Interventions

Interventions: DHEA replacement versus placebo Patients with primary and secondary adrenal insufficiency will be randomly allocated into tratment and placeco groups. An initial assessm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with at least a 4 year history of primary adrenal insufficiency and those with secondary adrenal insufficiency as a result of pituitary surgery for a non-functioning pituitary tumour who did not receive radiotherapy and who are on stable doses of full hormone replacement including growth hormone.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Pulse wave velocity Pulse wave analysis Endothelial function Blood tests for DHEA, high sensitivity C-reactive protein, plasminogen activator inhibitor-1, full lipid profile, testosterone, sex hormone binding globulin, oestradiol (males only), follicle stimulating hormone, luteinising hormone and liver function	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026